Edgewise announces Topline results for Becker Phase 2 Trial

As an early funder of Edgewise, CureDuchenne is pleased to share that the Phase 2 Trial of sevasemten in Becker muscular dystrophy met its primary endpoint of reduction in creatine kinase (CK), a biomarker associated with skeletal muscle damage.  Individuals treated with sevasemten also showed stabilization of NSAA, with a trend towards improvement at 12 months compared to placebo.  Sevasemten is an orally-administered experimental therapeutic aimed at protecting against contraction-induced damage by inhibiting fast skeletal myosin.   Edgewise indicated they are on track to complete recruitment in their pivotal trial in Becker, called Grand Canyon, early next year.  CureDuchenne is proud to have contributed to this program, which aims to be the first therapeutic option for Becker.

Link to press release HERE